As of 05/21/2025, Affymax's market capitalization has reached $59,592. According to our data, Affymax is the 48779th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 59,592 |
| Revenue (ttm) | 42,000 |
| Net Income (ttm) | 3.07 M |
| Shares Out | 74.49 M |
| EPS (ttm) | 0.08 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | n/a |
| Date | Market Cap | Change (%) |
|---|---|---|
| 05/21/2025 | $59,592 | 0% |
| 12/31/2024 | $59,592 | 33.33% |
| 12/29/2023 | $44,694 | -85% |
| 12/30/2022 | $297,960 | -33.33% |
| 12/31/2021 | $446,941 | -94% |
| 12/31/2020 | $7.45 M |
Affymax, Inc. is a company that currently does not have significant operations.
Previously, the company focused on developing drugs aimed at improving the treatment of serious and often life-threatening conditions in the United States.
| Country or region | United States |
| Founded | 2001 |
| IPO Date | n/a |
| Employees | 2 |
| CEO | Jonathan Couchman |
| Sector | Healthcare |
| Industry | Biotechnology |
| Address |
630 Fifth Avenue New York, Delaware 10020 United States |
| Website |
United States
